• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较手动与自动热盖治疗联合睑板腺按摩治疗干眼患者的疗效。

Comparison of manual versus automated thermal lid therapy with expression for meibomian gland dysfunction in patients with dry eye disease.

机构信息

From UCSD School of Medicine Department of Ophthalmology, Shiley Eye Institute, La Jolla, CA, USA.

出版信息

Sci Rep. 2024 Sep 27;14(1):22287. doi: 10.1038/s41598-024-72320-3.

DOI:10.1038/s41598-024-72320-3
PMID:39333153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11437139/
Abstract

To compare two types of lipid expression procedures to treat dry eye disease. Standardized treatment and evaluation methods were used in patients treated with either manual thermoelectric lipid expression (MiBoFlo) or automated lipid expression (Lipiflow) of the Meibomian glands. This was a contemporaneous, non-randomized study of both treatment methods. Treatment was per the manufacturers' recommendation. The primary outcome included two types of dry eye questionnaires as well as objective analysis of ocular surface including tear break up time, Schirmer testing, Osmolarity, and fluorescein staining. Baseline characteristics analyzed included floppy lid, conjunctivochalasis and lagophthalmos. Statistical analysis was performed correcting for baseline factors such as age and co existing pathology using multivariable analysis. Both treatments improved the results of the OSDI and SPEED dry eye questionnaire results. Both treatments resulted in improvement of many objective findings including SPK, lissamine green staining and tear break up time with the MiBoFlo showing more improvement than Lipiflow. OSDI was more sensitive to improvement of symptoms than the SPEED questionnaire. Manual expression with MiBoFlo device resulted in statistically more improvement in questionnaire scores than did automated expression with Lipiflow. Negative prognostic factors for symptomatic improvement included blepharitis, autoimmune disease and ocular allergies. Thermal lid therapy along with mechanical expression of lipids from the meibomian glands successfully treats dry eye symptoms and signs. Manual therapy with MiBoFlo resulted in more subjective and objective improvement scores than automated therapy with the Lipiflow device.

摘要

比较两种治疗干眼症的脂质表达方法。采用标准化治疗和评估方法,对接受手动热电脂质表达(MiBoFlo)或自动脂质表达(Lipiflow)治疗的患者的睑板腺进行治疗。这是两种治疗方法的同期、非随机研究。治疗方法按制造商的建议进行。主要结局包括两种干眼症问卷以及眼表的客观分析,包括泪膜破裂时间、泪液分泌试验、渗透压和荧光素染色。分析的基线特征包括眼睑松弛、结膜松弛和睑裂闭合不全。使用多变量分析校正年龄和并存病理等基线因素后,对统计学分析进行校正。两种治疗方法均改善了 OSDI 和 SPEED 干眼问卷结果。两种治疗方法均改善了许多客观发现,包括 SPK、丽丝胺绿染色和泪膜破裂时间,MiBoFlo 的改善程度优于 Lipiflow。OSDI 对症状改善的敏感性高于 SPEED 问卷。MiBoFlo 设备的手动表达在问卷评分方面的改善程度明显高于 Lipiflow 的自动表达。症状改善的负面预测因素包括睑缘炎、自身免疫性疾病和眼部过敏。热盖治疗联合机械性睑板腺脂质表达成功治疗干眼症状和体征。MiBoFlo 的手动治疗比 Lipiflow 设备的自动治疗在主观和客观改善评分方面更有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c050/11437139/c117e9203dc4/41598_2024_72320_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c050/11437139/12ebe2e66532/41598_2024_72320_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c050/11437139/c117e9203dc4/41598_2024_72320_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c050/11437139/12ebe2e66532/41598_2024_72320_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c050/11437139/c117e9203dc4/41598_2024_72320_Fig2_HTML.jpg

相似文献

1
Comparison of manual versus automated thermal lid therapy with expression for meibomian gland dysfunction in patients with dry eye disease.比较手动与自动热盖治疗联合睑板腺按摩治疗干眼患者的疗效。
Sci Rep. 2024 Sep 27;14(1):22287. doi: 10.1038/s41598-024-72320-3.
2
A single LipiFlow® Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months.单次 LipiFlow® 热脉动系统治疗可改善 9 个月的睑板腺功能并减轻干眼症状。
Curr Eye Res. 2012 Apr;37(4):272-8. doi: 10.3109/02713683.2011.631721. Epub 2012 Feb 10.
3
Effect of Thermoelectric Warming Therapy for the Treatment of Meibomian Gland Dysfunction.温热治疗对睑板腺功能障碍的疗效。
Am J Ophthalmol. 2022 Oct;242:181-188. doi: 10.1016/j.ajo.2022.06.013. Epub 2022 Jun 25.
4
Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial.全自动热作用治疗系统(LipiFlow®)治疗睑板腺功能障碍的疗效评估:前瞻性、随机、观察者设盲临床试验。
Ocul Surf. 2014 Apr;12(2):146-54. doi: 10.1016/j.jtos.2013.12.001. Epub 2014 Jan 22.
5
Efficacy and Safety evaluation of a single thermal pulsation system treatment (Lipiflow) on meibomian gland dysfunction: a randomized controlled clinical trial.单一热脉动系统治疗(Lipiflow)治疗睑板腺功能障碍的疗效和安全性评估:一项随机对照临床试验。
Int Ophthalmol. 2023 Apr;43(4):1175-1184. doi: 10.1007/s10792-022-02516-x. Epub 2022 Sep 16.
6
Clinical Efficacy of Immediate Manual Meibomian Gland Expression After Thermal Pulsation (LipiFlow) for Obstructive Meibomian Gland Dysfunction: Comparison With Thermal Pulsation.热脉动(Lipiflow)治疗阻塞性睑板腺功能障碍后立即进行手动睑板腺按摩的临床疗效:与热脉动的比较
Cornea. 2020 Aug;39(8):975-979. doi: 10.1097/ICO.0000000000002328.
7
LipiFlow for the treatment of dry eye disease.LipiFlow 治疗干眼病。
Cochrane Database Syst Rev. 2024 Feb 5;2(2):CD015448. doi: 10.1002/14651858.CD015448.pub2.
8
Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment.单次热脉冲治疗可改善睑板腺功能并减轻干眼症状(长达 12 个月)。
Clin Exp Ophthalmol. 2013 Aug;41(6):524-30. doi: 10.1111/ceo.12033. Epub 2012 Dec 14.
9
Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis.经向量热脉动系统(Lipiflow®)治疗睑板腺功能障碍的疗效和安全性:系统评价和荟萃分析。
Graefes Arch Clin Exp Ophthalmol. 2022 Jan;260(1):25-39. doi: 10.1007/s00417-021-05363-1. Epub 2021 Aug 10.
10
Preoperative Management of MGD with Vectored Thermal Pulsation before Cataract Surgery: A Prospective, Controlled Clinical Trial.白内障术前 Vectored 热脉冲治疗 MGD 的前瞻性对照临床试验
Semin Ophthalmol. 2021 Feb 17;36(1-2):2-8. doi: 10.1080/08820538.2021.1881567. Epub 2021 Feb 15.

引用本文的文献

1
Dry eye disease treatment improves subjective quality-of-life responses in patients with AMD, independent of disease stage.干眼症治疗可改善年龄相关性黄斑变性患者的主观生活质量反应,与疾病阶段无关。
PLoS One. 2025 Feb 6;20(2):e0318733. doi: 10.1371/journal.pone.0318733. eCollection 2025.

本文引用的文献

1
Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease.OC-01(盐酸伐尼克兰溶液)鼻喷雾剂治疗轻、中、重度干眼患者的体征和症状的双侧效应。
Clin Ther. 2022 Nov;44(11):1463-1470. doi: 10.1016/j.clinthera.2022.09.013. Epub 2022 Oct 28.
2
Effect of Thermoelectric Warming Therapy for the Treatment of Meibomian Gland Dysfunction.温热治疗对睑板腺功能障碍的疗效。
Am J Ophthalmol. 2022 Oct;242:181-188. doi: 10.1016/j.ajo.2022.06.013. Epub 2022 Jun 25.
3
A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study.
一项评估OC-01(伐尼克兰溶液)鼻喷雾剂治疗干眼症的长期(12周)疗效和安全性的II期随机试验:MYSTIC研究。
Ocul Surf. 2022 Apr;24:15-21. doi: 10.1016/j.jtos.2021.12.007. Epub 2021 Dec 15.
4
Dry Eye Disease after Cataract Surgery: Study of its Determinants and Risk Factors.白内障手术后干眼:其决定因素和危险因素的研究。
Turk J Ophthalmol. 2020 Jun 27;50(3):133-142. doi: 10.4274/tjo.galenos.2019.45538.
5
Cataract surgery and dry eye disease: A review.白内障手术与干眼症:综述
Eur J Ophthalmol. 2020 Sep;30(5):840-855. doi: 10.1177/1120672120929958. Epub 2020 Jun 9.
6
Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial.iLUX与Lipiflow治疗睑板腺功能障碍及症状的比较:一项随机临床试验
Clin Ophthalmol. 2020 Feb 12;14:405-418. doi: 10.2147/OPTH.S234008. eCollection 2020.
7
The Effect of a Ptosis Procedure Compared to an Upper Blepharoplasty on Dry Eye Syndrome.上睑下垂手术与上睑成形术治疗干眼症的效果比较。
Am J Ophthalmol. 2020 Apr;212:1-6. doi: 10.1016/j.ajo.2019.11.021. Epub 2019 Nov 23.
8
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.一项评估 OTX-101 眼用溶液 0.09%治疗干眼症的 3 期、随机、双盲研究。
Ophthalmology. 2019 Sep;126(9):1230-1237. doi: 10.1016/j.ophtha.2019.03.050. Epub 2019 Apr 6.
9
TearCare system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare treatment on subjects with dry eye disease.泪液护理系统扩展研究:对患有干眼症的受试者进行第二次泪液护理治疗,为期12个月,评估其安全性、有效性和耐用性。
Clin Ophthalmol. 2019 Jan 22;13:189-198. doi: 10.2147/OPTH.S191588. eCollection 2019.
10
A novel system, TearCare, for the treatment of the signs and symptoms of dry eye disease.一种用于治疗干眼症体征和症状的新型系统——泪液护理系统(TearCare)。
Clin Ophthalmol. 2018 Apr 10;12:683-694. doi: 10.2147/OPTH.S160403. eCollection 2018.